THE US Food and Drug
Administration has flagged a
proposed ban on compounding of
medications which are “essentially
copies of commercially available or
approved drug products”.
The proposals would see the
FDA implement restrictions on
compounded copies of approved
medications, with the organisation
saying they pose a higher risk
to patients because they have
not been evaluated for safety,
effectiveness and quality.
“Such compounding would
also undermine the new drug
approval and over-the counter drug
monograph systems in the United
States,” the FDA said, with the
proposals now open for a 90 day
public comment period.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jul 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.